|
ABCD worldwide
audits
Worldwide audit of new diabetes therapies
ABCD is now cloning some of its N3 audit tools onto a secure server accessible
world-wide for audit purposes. Everything is exactly the same except
that the patient identifier is encrypted. Instead of users registering
centres and sites as in the N3 versions, users register countries and
centres in those countries. The sophisticated analysis tool will be
available for Centres to analyse their data, but super-users within the
country will be able to analyse the national data using the same
facilities. At the same time all the anonymised data will be available for
worldwide data analysis.
The tools to be made available
in this way were with regard to
exenatide qw,
dapagliflozin,
canagliflozin and
FreeStyle Libre and always the first country to register is
Northern Ireland. The Northern Ireland centres are historically very
active contributors to ABCD nationwide audits, but Northern Ireland is
not on N3 and hence has to use the worldwide tool.
Anyone from any Centre in any Country interested in registering to use
the audit tools in this way should fill in the
online application form or in the case of FreeStyle Libre
this application form For further information contact Dr Bob
Ryder, clinical lead, ABCD nationwide audits of new diabetes therapies
and devices by
clicking here.
Endobarrier worldwide registry
ABCD has established a worldwide Endobarrier registry of to capture
routine clinical data on safety and efficacy of this exciting new
treatment. Because the technology is based on the technologies
developed for our other audits of new therapies, the tool has the well
honed bespoke facility for capturing changes in other diabetes therapies
with time. Also the sophisticated data analysis tool developed for the exenatide QW, dapagliflozin, canagliflozin
and FreeStyle Libre audit tools. The analysis
is available to deploy for use by individual centres, individual
countries, groups of countries, or all worldwide data.
Click here for more information.
|
